<DOC>
	<DOCNO>NCT01744665</DOCNO>
	<brief_summary>To evaluate molecular relapse free rate 6 month stop nilotinib therapy patient achieve MR4.5</brief_summary>
	<brief_title>Safety Efficacy CML Patients Who Switch Nilotinib Stop Treatment After Achieving Sustaining MR4.5 .</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Diagnosis CML Treated least 1 year imatinib BcrAbl level PCR must less equal 0.1 % great 0.0032 % PCR report International scale . This confirm screen Written informed consent obtain prior screen procedure perform T315I mutation Prior imatinib failure accelerate phase blast crisis CML Impaired cardiac function ( define futher protocol ) Pregnant lactate woman Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CML , chronic myeloid leukemia , stop , niotinib , discontinue , imatinib , switch , MR4.5 , undetectable , bcr-abl</keyword>
</DOC>